Zoetis Inc. (NYSE:ZTS) Stock Position Raised by Romano Brothers AND Company

Romano Brothers AND Company boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 2.3% during the third quarter, HoldingsChannel.com reports. The fund owned 3,391 shares of the company’s stock after acquiring an additional 75 shares during the period. Romano Brothers AND Company’s holdings in Zoetis were worth $663,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Webster Bank N. A. boosted its position in Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after purchasing an additional 82 shares during the period. Quarry LP boosted its holdings in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the period. LRI Investments LLC bought a new position in shares of Zoetis during the first quarter worth about $43,000. Central Valley Advisors LLC acquired a new stake in shares of Zoetis in the 2nd quarter worth about $49,000. Finally, Future Financial Wealth Managment LLC bought a new stake in Zoetis in the 1st quarter valued at about $51,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Down 4.0 %

Shares of ZTS stock opened at $181.52 on Friday. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The stock has a 50-day simple moving average of $189.23 and a 200 day simple moving average of $177.58. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a market capitalization of $82.24 billion, a P/E ratio of 35.52, a P/E/G ratio of 2.94 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter in the previous year, the company posted $1.41 EPS. The business’s revenue was up 8.3% compared to the same quarter last year. On average, sell-side analysts expect that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.95%. Zoetis’s dividend payout ratio (DPR) is presently 33.86%.

Analysts Set New Price Targets

Several brokerages have commented on ZTS. BTIG Research raised their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. JPMorgan Chase & Co. raised their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Finally, Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.